Meng Xian-Ying, Zhang Qiang, Li Qun, Lin Shan, Li Jie
Department of Thyroid Surgery, First Hospital, Jilin University, Changchun, Jilin Province, China.
Department of Geratology, First Hospital, Jilin University, Changchun, Jilin Province, China
J Int Med Res. 2014 Jun;42(3):619-27. doi: 10.1177/0300060513505485. Epub 2014 Mar 26.
To measure the levels of cyclo-oxygenase (COX)-2, matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) immunostaining in papillary thyroid carcinoma (PTC) and benign thyroid tumours, and to investigate potential correlations between their levels and clinicopathological characteristics.
The levels of immunohistochemical staining of COX-2, MMP-9 and VEGF proteins were measured in tumours from patients with PTC and compared with specimens from patients with benign thyroid tumours. The association between the levels of COX-2, MMP-9 and VEGF proteins and clinicopathological characteristics in patients with PTC was also analysed.
A total of 66 patients with PTC and 40 patients with benign thyroid tumours participated in the study. The rates of positive immunostaining for COX-2, MMP-9 and VEGF in PTC tumours were significantly higher than those in benign thyroid tumours. There were significant positive associations between positive immunostaining for COX-2, MMP-9 and VEGF proteins and age (≥45 years), clinical stage (III-IV) and tumour diameter (≥ 2 cm).
Combined immunohistochemical evaluation of the levels of COX-2, MMP-9 and VEGF in PTC might be a useful marker for the diagnosis of PTC.
检测甲状腺乳头状癌（PTC）和甲状腺良性肿瘤中环氧化酶（COX）-2、基质金属蛋白酶（MMP）-9和血管内皮生长因子（VEGF）的免疫染色水平，并探讨其水平与临床病理特征之间的潜在相关性。
检测PTC患者肿瘤组织中COX-2、MMP-9和VEGF蛋白的免疫组化染色水平，并与甲状腺良性肿瘤患者的标本进行比较。同时分析PTC患者中COX-2、MMP-9和VEGF蛋白水平与临床病理特征之间的关联。
共有66例PTC患者和40例甲状腺良性肿瘤患者参与本研究。PTC肿瘤中COX-2、MMP-9和VEGF的免疫染色阳性率显著高于甲状腺良性肿瘤。COX-2、MMP-9和VEGF蛋白免疫染色阳性与年龄（≥45岁）、临床分期（III-IV期）和肿瘤直径（≥2 cm）之间存在显著正相关。
联合免疫组化评估PTC中COX-2、MMP-9和VEGF的水平可能是诊断PTC的有用标志物。
